Ebola Vaccination
Ebola vaccines spur lasting immunity in children and adults, trials show
Two randomized, placebo-controlled trials of three Ebola vaccine regimens demonstrated that they are safe and spur lasting antibodies in both children and adults, according to findings reported in The New England Journal of Medicine.
Uganda declares first Sudan ebolavirus outbreak in a decade
Health authorities in Uganda on Tuesday declared an Ebola outbreak after a case of Sudan ebolavirus was confirmed.
Rapid testing can detect Ebola-related deaths, reducing transmission through burials
An FDA-licensed rapid antigen test was able to detect Ebola-related deaths among nearly 500 people who died during a large outbreak in the Democratic Republic of the Congo, according to a new study published in Emerging Infectious Diseases.
ACIP recommends universal hepatitis B vaccination for adults aged 19 to 59 years
The CDC’s Advisory Committee on Immunization Practices voted unanimously, 15-0, on Wednesday to recommend hepatitis B vaccination for all adults aged 19 to 59 years.
‘Immense concern’ over Ivory Coast’s first case of Ebola in decades
Heath officials expressed concern after Ivory Coast reported its first case of Ebola virus in decades.
FDA approves Merck’s Ebola vaccine, Ervebo
Merck’s Ebola vaccine, Ervebo, has been approved by the FDA, the company announced, calling it “another important milestone in the global response to Ebola virus disease.”
In a first, WHO prequalifies Merck’s Ebola vaccine
One day after winning conditional approval in Europe, Merck’s Ebola vaccine received prequalification status from WHO, giving it the agency’s stamp of approval as a safe and effective prevention tool against the deadly virus.
European Union conditionally approves Merck’s Ebola vaccine, Ervebo
The European Commission granted conditional approval for Ervebo, Merck’s investigational Ebola virus vaccine, which has been used widely and effectively in the ongoing Ebola outbreak in the Democratic Republic of the Congo, or DRC.
‘Not over the finish line’: Ebola vaccine development remains important
The next generation of Ebola vaccines may be able to address deficiencies seen in the first generation, researchers said, highlighting the importance of continuing to evaluate new candidates even as the world nears the approval of the first licensed vaccine against the disease.
Was it the right decision to introduce a second vaccine in the DRC Ebola outbreak?
For more than a year, only Merck’s investigational V920 vaccine was used in the Ebola outbreak in the Democratic Republic of the Congo, or DRC. The vaccine, which has been shown to be more than 97% effective, can be used as both pre- and post-exposure prophylaxis. In September, WHO confirmed that a second vaccine would be used to help prevent further spread of the virus. Infectious Disease News asked Daniel R. Lucey, MD, MPH, adjunct professor of medicine and infectious diseases at Georgetown University, if introducing the second vaccine was the right decision.